Skip to main content
Figure 7 | Journal of Translational Medicine

Figure 7

From: Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

Figure 7

Peptide-specific interferon-γ release of CTLs. PBMCs of HLA-A24-positive prostate cancer patient (case 6) were stimulated four times with four kinds of AMACR peptide (AMACR1-4)-pulsed APCs and peptide-specific interferon-γ release was analyzed by ELISPOT assay. CTLs could release interferon-γ in response to AMACR1, 2 and 3 peptides, but not in response to AMACR4 peptide or HIV peptide.

Back to article page